Single-Photon Emission Computed Tomography/Computed Tomography in Endocrinology

Seminars in Nuclear Medicine

Volumn 36, Issue 4, 2006, Pages 267-274

  Krausz, Yodphat ^a   Israel, Ora ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Department of Nuclear Medicine ^*  (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYTRYPTOPHAN; CARBON 11; DOPA; FLUORINE 18; FLUORODEOXYGLUCOSE; INDIUM 111; IODINE 123; IODINE 131; LANREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90]; MEDRONATE TECHNETIUM TC 99M; MEMBRANE RECEPTOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; OCTREOTIDE; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90]; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG UPTAKE; ENDOCRINE TUMOR; HUMAN; IMAGE ANALYSIS; MATHEMATICAL MODEL; NERVOUS SYSTEM TUMOR; NEURAL CREST TUMOR; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PARATHYROID ADENOMA; PHEOCHROMOCYTOMA; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; ULTRASOUND;

ENDOCRINE GLAND NEOPLASMS; ENDOCRINOLOGY; EQUIPMENT DESIGN; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; SUBTRACTION TECHNIQUE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748038026     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2006.05.002     Document Type: Review

References (64)

1. Bocher M., Balan A., Krausz Y., et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med 27 (2000) 619-627
2. von Schulthess G.K., and Pelc N.J. Integrated-modality imaging: the best of both worlds. Acad Radiol 9 (2002) 1241-1244
3. Keidar Z., Israel O., and Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med 33 (2003) 205-218
4. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging?. Eur J Nucl Med Mol Imaging 32 (2005) 521-524
5. van der Lely A.J., de Herder W.W., Krenning E.P., et al. Octreoscan radioreceptor imaging. Endocrine 20 (2003) 307-311
6. Noone T.C., Hosey J., Firat Z., et al. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19 (2005) 195-211
7. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
8. Krausz Y., Bar-Ziv J., de Jong R.B., et al. Somatostatin receptor scintigraphy in the management of gastroenteropancreatic tumors. Amer J Gastroenterol 93 (1998) 66-70
9. Bombardieri E., Maccauro M., De Deckere E., et al. 2001 Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12 suppl 2 (2001) S51-S61
10. Kwekkeboom D.J., and Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 32 (2002) 84-91
11. Otte A., Mueller-Brand J., Dellas S., et al. Yttrium-90-labelled somatostatin-analog for cancer treatment. Lancet 351 (1998) 417-418
12. De Jong M., Breeman W.A., Bernard H.F., et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogs. Q J Nucl Med 43 (1999) 356-366
13. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
14. Lebtahi R., Cadiot G., Sarda L., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38 (1997) 853-858
15. Termanini B., Gibril F., Reynolds J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112 (1997) 335-347
16. de Jong M., Breeman W.A., Valkema R., et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 suppl 1 (2005) 13S-17S
17. Gibril F., Reynolds J.C., Chen C.C., et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40 (1999) 539-553
18. Forster G.J., Laumann C., Nickel O., et al. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool. Eur J Nucl Med Mol Imaging 30 (2003) 32-39
19. Perault C., Schvartz C., Wampach H., et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. J Nucl Med 38 (1997) 1234-1242
20. Even-Sapir E., Keidar Z., Sachs J., et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 42 (2001) 998-1004
21. Krausz Y., Keidar Z., Kogan I., et al. SPECT/CT hybrid imaging with In111-Pentetreotide in assessment of Neuroendocrine Tumors. Clin Endocrinol 59 (2003) 565-573
22. Pfannenberg A.C., Eschmann S.M., Horger M., et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30 (2003) 835-843
23. Schillaci O. Functional-anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm 19 (2004) 129-134
24. Pacak K., Linehan W.M., Eisenhofer G., et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134 (2001) 315-329
25. Freitas J.E. Adrenal cortical and medullary imaging. Semin Nucl Med 25 (1995) 235-250
26. Mozley P.D., Kim C.K., Mohsin J., et al. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med 35 (1994) 1138-1144
27. 131I metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 25 (2000) 440-442
28. Ozer S., Dobrozemsky G., Kienast O., et al. Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy. Nuklearmedizin 43 (2004) 164-170
29. Bar-Shalom R., Keidar Z., and Krausz Y. Prospective image fusion: the role of SPECT/CT and PET/CT. In: Henkin R.E., Bova D., Dillehay G.L., et al. (Eds). Nuclear Medicine. (ed 2) (2006), St. Louis, CV Mosby 1527-1544
30. Klein M., Kopelewitz B., Krausz Y., et al. Contribution of SPECT/CT to bridging between MIBG scan and diagnostic CT. J Nucl Med 45 (2004) 361 (abstr)
31. Schillaci O., Danieli R., Manni C., et al. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation?. Nucl Med Commun 25 (2004) 705-710
32. Biasotti S., Garaventa A., Villavecchia G.P., et al. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000 35 (2000) 153-155
33. Leung A., Shapiro B., Hattner R., et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38 (1997) 1352-1357
34. Rufini V., Fisher G.A., Shulkin B.L., et al. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 37 (1996) 1464-1468
35. Gelfand M.J., Elgazzar A.H., Kriss V.M., et al. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35 (1994) 1753-1757
36. Bonnin F., Lumbroso J., Tenenbaum F., et al. Refining interpretation of MIBG scans in children. J Nucl Med 35 (1994) 803-810
37. 131I-MIBG. J Nucl Med 42 (2001) 237-247
38. Diehl M., Risse J.H., Brandt-Mainz K., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28 (2001) 1671-1676
39. 131I scans in patients with thyroid cancer. Semin Nucl Med 30 (2000) 115-132
40. 131I whole body scanning. Nuklearmedizin 42 (2003) 55-62
41. 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med 44 (2003) 1905-1910
42. 131I-avid sites in differentiated thyroid cancer. J Nucl Med 45 (2004) 349 (abstr)
43. Ruf J., Lehmkuhl L., Bertram H., et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 25 (2004) 1177-1182
44. 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 1435-1442
45. 131)I using Monte Carlo simulation. J Nucl Med 43 (2002) 1101-1109
46. Clark O.H. How should patients with primary hyperparathyroidism be treated?. J Clin Endocrinol Metab 88 (2003) 3011-3014
47. Bergenfelz A., Lindblom P., Tibblin S., et al. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 236 (2002) 543-551
48. van Vroonhoven T.J., and van Dalen A. Successful minimally invasive surgery in primary hyperparathyroidism after combined preoperative ultrasound and computed tomography imaging. J Intern Med 243 (1998) 581-587
49. Ohshima A., Simizu S., Okido M., et al. Endoscopic neck surgery: current status for thyroid and parathyroid diseases. Biomed Pharmacother 56 suppl 1 (2002) 48s-52s
50. Medrano C., Hazelrigg S.R., Landreneau R.J., et al. Thoracoscopic resection of ectopic parathyroid glands. Ann Thorac Surg 69 (2000) 221-223
51. Mariani G., Gulec S.A., Rubello D., et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med 44 (2003) 1443-1458
52. Denham D.W., and Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 186 (1998) 293-305
53. Gotthardt M., Lohmann B., Behr T.M., et al. Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature. World J Surg 28 (2004) 100-107
54. Lumachi F., Ermani M., Basso S., et al. Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen?. Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocr Relat Cancer 8 (2001) 63-69
55. Arici C., Cheah W.K., Ituarte P.H., et al. Can localization studies be used to direct focused parathyroid operations?. Surgery 129 (2001) 720-729
56. Gotway M.B., Reddy G.P., Webb W.R., et al. Comparison between MR imaging and 99mTc-MIBI scintigraphy in the evaluation of recurrent or persistent hyperparathyroidism. Radiology 218 (2001) 783-790
57. Lorberboym M., Minski I., Macadziob S., et al. Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. J Nucl Med 44 (2003) 904-908
58. Rubello D., Casara D., Fiore D., et al. An ectopic mediastinal parathyroid adenoma accurately located by a single-day imaging protocol of Tc-99m pertechnetate-MIBI subtraction scintigraphy and MIBI-SPECT-computed tomographic image fusion. Clin Nucl Med 27 (2002) 186-190
59. Ng P., Lenzo N.P., McCarthy M.C., et al. Ectopic parathyroid adenoma localised with sestamibi SPECT and image-fused computed tomography. Med J Aust 179 (2003) 485-487
60. Profanter C., Prommegger R., Gabriel M., et al. Computed axial tomography-MIBI image fusion for preoperative localization in primary hyperparathyroidism. Am J Surg 187 (2004) 383-387
61. Profanter C., Wetscher G.J., Gabriel M., et al. CT-MIBI image fusion: a new preoperative localization technique for primary, recurrent, and persistent hyperparathyroidism. Surgery 135 (2004) 157-162
62. Kaczirek K., Prager G., Kienast O., et al. Combined transmission and 99mTc-sestamibi emission tomography for localization of mediastinal parathyroid glands. Nuklearmedizin 42 (2003) 220-223
63. Gayed I.W., Kim E.E., Broussard W.F., et al. The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J Nucl Med 46 (2005) 248-252
64. Krausz Y., Bettman L., Guralnik L., et al. Tc99m-MIBI SPECT/CT in Primary Hyperparathyroidism. World J Surg 30 (2006) 76-83